The latest food and beverage industry news and trend analysis

Solar Foods, a global leader in sustainable alternative proteins, has announced the receipt of a patent from the United States Patent and Trademark Office covering the production process of its flagship protein ingredient, Solein®.

The patent grants the Finnish food-tech company exclusive rights to produce Solein using its proprietary gas fermentation process and a unique microorganism discovered in the Finnish wilderness. The US approval adds to a robust intellectual property portfolio, joining existing patents in major global markets including Europe, Canada, Australia, and China.

IP Security in a Major Protein Market

Securing intellectual property rights in the US is a critical milestone for Solar Foods as it transitions from research and development into commercial scale. The United States represents one of the largest and most lucrative protein-consuming markets globally, making it a primary target for alternative protein innovators.

Juha-Pekka Pitkänen, Chief Scientific Officer at Solar Foods, stated that the patent allows the company to bring its "completely new harvest" to the food industry. He emphasised that the microbe, discovered nearly a decade ago, is extremely well-suited for a variety of product categories as a safe, highly nutritious, and functional ingredient.

Technical Process and Supply Chain Stability

Solein is produced using a bioprocess that effectively bypasses traditional agriculture. By utilising gas fermentation, the system feeds a single microbe with carbon dioxide and hydrogen, converting these gases into a nutrient-dense protein powder.

This method offers several distinct B2B advantages for food manufacturers:

• Agricultural Independence 🌾 Production is completely decoupled from land use, weather patterns, and climate conditions, allowing facilities to be located anywhere in the world.

• Stable Supply and Pricing 🏭 The continuous, indoor fermentation process offers a reliable ingredient supply, insulating manufacturers from the price volatility associated with conventional commodity crops.

• Nutritional Parity 🧬 The resulting ingredient features a unique nutritional profile that combines the complete amino acid benefits of animal-based proteins with the sustainability metrics of plant-based alternatives.

Commercialisation Strategy and Regulatory Milestones

Solar Foods has officially commenced the commercialisation of Solein in the United States, strategically focusing initial efforts on the high-margin Health and Performance nutrition market. This sector is particularly receptive to clean-label, high-density protein alternatives.

The US rollout follows successful early market validation in Singapore, where products containing Solein have already been made available to consumers. Looking ahead to broader international expansion, the company anticipates receiving regulatory approval for Solein in both the European Union and the United Kingdom during 2026.

Scaling Production Infrastructure

To meet projected global demand, Solar Foods is actively scaling its manufacturing infrastructure. The company’s first commercial-scale facility, Factory 01, began operations in 2024 with an annual capacity of 160 tons.

Planning is currently underway for a massive expansion via Factory 02, which is designed to increase production capacity to 6,400 tons annually. The final investment decision for Factory 02 is expected to be made in 2026, with the first phase of the facility slated to become operational by the end of 2028. As the company proves its model, it intends to deploy a network of decentralised Solein factories globally, reshaping how bulk protein ingredients are sourced and produced.